Author:
Yu Dahai,Qu Bingjie,Osuagwu Uchechukwu Levi,Pickering Karen,Baker John,MBChB Richard Cutfield,Cai Yamei,Orr-Walker Brandon J,Sundborn Gerhard,Zhao Zhanzheng,Simmons David
Abstract
Abstract
Background
This study aimed to examine the association between the incident onset of T2DM and 5- and 10-year risks of CVD and HF in people with IGT identified in primary care in South and West Auckland, New Zealand (NZ) between 1994 and 2019.
Methods
We compared CVD and HF risks in patients with IGT and with/without T2D newly diagnosed within the exposure window (1–5 years). Tapered matching and landmark analysis (to account for immortal bias) were used to control for potential effects of known confounders.
Results
Among 26,794 patients enrolled with IGT, 845 had T2D newly diagnosed within 5 years from enrolment (landmark date) and 15,452 did not have T2D diagnosed. Patients progressing to T2D (vs. those not progressing) had a similar 5-year risk for CVD (hazard ratio 1.19; 95% CI 0.61–2.32) but significantly higher 10-year risk of CVD (2.45(1.40–4.29)), 5-year risk of HF (1.94(1.20–3.12)) and 10-year risk of HF (2.84(1.83–4.39). The association between the onset of T2D and risk of 10-year risk of CVD, 5-year and 10-year risk of HF was more likely among men, the socioeconomically deprived, those currently smoking, patients with higher metabolic measures and/or those with lower renal function. Patients of NZ European ethnicity had a lower 10-year risk of CVD.
Conclusions
The study suggests that the diagnosis of T2D mediates the risk of CVD and HF in people with IGT. The development of risk scores to identify and better manage individuals with IGT at high risk of T2D is warranted.
Funder
Ministry of Health, New Zealand
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine,Endocrinology, Diabetes and Metabolism
Reference46 articles.
1. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011 July 02;378(9785):31–40.
2. Katikireddi SV, Morling JR, Bhopal R. Is there a divergence in time trends in the prevalence of impaired glucose tolerance and diabetes? A systematic review in south asian populations. Int J Epidemiol 2011 December 01;40(6):1542–53.
3. Cowie CC, Rust KF, Ford ES, Eberhardt MS, Byrd-Holt DD, Li C et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988–1994 and 2005–2006. Diabetes Care 2009 February 01;32(2):287–94.
4. Coppell KJ, Mann JI, Williams SM, Jo E, Drury PL, Miller JC et al. Prevalence of diagnosed and undiagnosed diabetes and prediabetes in New Zealand: findings from the 2008/09 adult Nutrition Survey. N Z Med J 2013 March 01;126(1370):23–42.
5. Barr ELM, Zimmet PZ, Welborn TA, Jolley D, Magliano DJ, Dunstan DW et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the australian diabetes, obesity, and Lifestyle Study (AusDiab). Circulation 2007 July 10;116(2):151–7.